Daré Bioscience, Inc. (DARE) Financial Ratios
14 years of historical data (2011–2024) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
5.25
-4% vs avg
5yr avg: 5.50
30Y Low5.5·High5.5
P/B Ratio
↑
N/A
—
5yr avg: 4.74
30Y Low0.5·High29.0
ROE
↓
N/A
—
5yr avg: -441.5%
30Y Low-398%·High-84%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
DARE Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Daré Bioscience, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis. On a free-cash-flow basis, the stock trades at 5.3x P/FCF, roughly in line with the 5-year average of 5.5x.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $25M | $27M | $27M | $70M | $122M | $40M | $13M | $8M | $7M | $111M | $854M |
| Enterprise Value | $11M | $12M | $18M | $36M | $71M | $36M | $9M | $823070 | $-564671 | $89M | $799M |
| P/E Ratio → | -6.06 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 2587.71 | 2709.59 | 9.61 | 7.02 | — | — | — | — | — | 145.27 | — |
| P/B Ratio | — | — | — | 6.32 | 3.16 | — | 28.97 | 1.13 | 0.53 | 8.49 | 17.53 |
| P/FCF | 5.25 | 5.50 | — | — | — | — | — | — | — | — | — |
| P/OCF | 4.69 | 4.91 | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
DARE EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1238.30 | 6.38 | 3.60 | — | — | — | — | — | 116.38 | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | 2.51 | — | — | — | — | — | — | — | — | — |
DARE Profitability
Margins and return-on-capital ratios measuring operating efficiency
Daré Bioscience, Inc. earns an operating margin of -239692.2%. Operating margins have compressed from -313.9% to -239692.2% over the past 3 years, signaling potential cost pressures or competitive headwinds.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | -146110.2% | -146110.2% | -670.6% | -201.4% | — | — | — | — | — | 47.8% | — |
| Operating Margin | -239692.2% | -239692.2% | -1101.9% | -313.9% | — | — | — | — | — | -4850.4% | — |
| Net Profit Margin | -41430.9% | -41430.9% | -1074.2% | -309.5% | — | — | — | — | — | -5131.2% | — |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | -994.7% | -124.1% | -205.8% | — | -398.0% | -167.2% | -87.1% | -127.1% | -84.2% |
| ROA | -18.7% | -18.7% | -92.6% | -62.1% | -122.2% | -365.5% | -186.8% | -151.6% | -44.3% | -67.8% | -60.2% |
| ROIC | — | — | — | — | — | — | — | -447.9% | — | — | — |
| ROCE | -3624.9% | -3624.9% | -475.8% | -120.8% | -197.1% | -3185.4% | -334.9% | -168.6% | -65.7% | -89.9% | -69.3% |
DARE Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $16M exceeds total debt of $1M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | 0.04 | 0.01 | — | 1.82 | — | — | 0.98 | 0.42 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | — | — | -3.08 | -1.33 | — | -9.03 | -1.01 | -0.57 | -1.69 | -1.14 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | -2.99 | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | — | — | -34.65 | -16.61 | -15.28 |
Net cash position: cash ($16M) exceeds total debt ($1M)
DARE Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
The current ratio of 0.85x is below 1.0, meaning current liabilities exceed current assets. The current ratio has declined from 1.36x to 0.85x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.85 | 0.85 | 0.86 | 1.36 | 3.44 | 0.91 | 1.15 | 6.64 | 8.64 | 2.17 | 4.73 |
| Quick Ratio | 0.85 | 0.85 | 0.86 | 1.36 | 3.44 | 0.91 | 1.15 | 375.72 | 8.31 | 2.28 | 4.82 |
| Cash Ratio | 0.73 | 0.73 | 0.51 | 1.10 | 3.22 | 0.61 | 0.85 | 6.24 | 7.82 | 2.06 | 4.65 |
| Asset Turnover | — | 0.00 | 0.13 | 0.23 | — | — | — | — | — | 0.02 | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 8579.66 | 123.39 | 62.17 | — | — | — | — | — | — | — |
DARE Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Daré Bioscience, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | 19.0% | 18.2% | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $8M | $7M | $7M | $5M | $3M | $1M | $894368 | $269356 | $1M | $3M |
Peer Comparison
Compare DARE with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 DAREYou | $25M | -6.1 | — | 5.3 | -146110.2% | -239692.2% | — | — | — |
 TPVG | $243M | 4.9 | 9.1 | — | 83.5% | 77.9% | 14.1% | 7.2% | 6.2 |
 EVAX | $26M | -3.4 | — | — | 99.7% | -122.7% | -100.5% | -295.2% | — |
 CODA | $134M | 32.2 | 17.9 | 22.2 | 66.5% | 17.1% | 7.4% | 11.2% | 0.1 |
 ANIP | $2B | 25.3 | 9.0 | 9.6 | — | 12.6% | 16.2% | 11.2% | 1.6 |
 CRVS | $1B | -27.5 | — | — | — | — | -32.6% | -78.1% | — |
 TXMD | $23M | -10.6 | — | 31.8 | 100.0% | -270.3% | -7.7% | -11.4% | — |
 HIMS | $7B | 50.3 | 42.7 | 89.6 | 59.3% | 5.2% | 25.2% | 10.7% | 6.4 |
 PRGO | $2B | -1.1 | 7.4 | 11.1 | 35.1% | 8.1% | -39.3% | 3.7% | 5.8 |
 ABBV | $358B | 85.5 | 15.0 | 20.1 | 70.2% | 32.8% | 6214.7% | 23.9% | 2.4 |
 PFE | $151B | 19.5 | 10.7 | 16.6 | 70.3% | 24.7% | 8.9% | 7.5% | 3.3 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 14 years · Updated daily
See DARE's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs DARE Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare DARE vs TPVG
Side-by-side business, growth, and profitability comparison vs TriplePoint Venture Growth BDC Corp..
Start ComparisonDARE — Frequently Asked Questions
Quick answers to the most common questions about buying DARE stock.
What is Daré Bioscience, Inc.'s P/E ratio?
Daré Bioscience, Inc.'s current P/E ratio is -6.1x. This places it at the 50th percentile of its historical range.
Is DARE stock overvalued?
Based on historical data, Daré Bioscience, Inc. is trading at a P/E of -6.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Daré Bioscience, Inc.'s profit margins?
Daré Bioscience, Inc. has -146110.2% gross margin and -239692.2% operating margin.